$HCTI
Healthcare Triangle, Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024098548 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $2.413M $7.779M
YoY Change -68.98% -34.9%
Cost Of Revenue $1.691M $6.072M
YoY Change -72.15% -28.75%
Gross Profit $722.0K $1.707M
YoY Change -57.7% -50.2%
Gross Profit Margin 29.92% 21.94%
Selling, General & Admin $1.371M $2.470M
YoY Change -44.49% -25.04%
% of Gross Profit 189.89% 144.7%
Research & Development $175.0K $54.00K
YoY Change 224.07% -96.33%
% of Gross Profit 24.24% 3.16%
Depreciation & Amortization $343.0K $710.0K
YoY Change -51.69% -21.89%
% of Gross Profit 47.51% 41.59%
Operating Expenses $1.889M $3.231M
YoY Change -41.54% -43.07%
Operating Profit -$1.167M -$1.524M
YoY Change -23.43% -32.18%
Interest Expense -$80.00K -$420.0K
YoY Change -80.95% 663.64%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.247M -$1.939M
YoY Change -35.69% -15.77%
Income Tax $2.000K $4.000K
% Of Pretax Income
Net Earnings -$1.249M -$1.943M
YoY Change -35.72% -16.93%
Net Earnings / Revenue -51.76% -24.98%
Basic Earnings Per Share -$0.22 -$0.45
Diluted Earnings Per Share -$0.22 -$0.46
COMMON SHARES
Basic Shares Outstanding 5.667M shares 5.667M shares 4.278M shares
Diluted Shares Outstanding 5.666M shares 4.278M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.00K $80.00K
YoY Change -65.0% -98.07%
Cash & Equivalents $28.00K $75.00K
Short-Term Investments
Other Short-Term Assets $146.0K $622.0K
YoY Change -76.53% 166.95%
Inventory
Prepaid Expenses
Receivables $1.610M $4.000K
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.784M $4.893M
YoY Change -63.54% -55.84%
LONG-TERM ASSETS
Property, Plant & Equipment $17.00K $49.00K
YoY Change -65.31% -35.53%
Goodwill $1.289M
YoY Change 0.0%
Intangibles $2.965M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.982M $9.573M
YoY Change -68.85% -30.55%
TOTAL ASSETS
Total Short-Term Assets $1.784M $4.893M
Total Long-Term Assets $2.982M $9.573M
Total Assets $4.766M $14.47M
YoY Change -67.05% -41.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.298M $1.161M
YoY Change 97.93% -20.91%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.082M $3.479M
YoY Change -68.9% 41.83%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.084M $6.852M
YoY Change -11.21% 35.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $500.0K $1.490M
YoY Change -66.44% -33.09%
Total Long-Term Liabilities $500.0K $1.490M
YoY Change -66.44% -33.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.084M $6.852M
Total Long-Term Liabilities $500.0K $1.490M
Total Liabilities $6.584M $8.339M
YoY Change -21.05% 14.44%
SHAREHOLDERS EQUITY
Retained Earnings -$29.53M -$19.58M
YoY Change 50.83% 163.86%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.818M $6.127M
YoY Change
Total Liabilities & Shareholders Equity $4.766M $14.47M
YoY Change -67.05% -41.82%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$1.249M -$1.943M
YoY Change -35.72% -16.93%
Depreciation, Depletion And Amortization $343.0K $710.0K
YoY Change -51.69% -21.89%
Cash From Operating Activities $715.0K $0.00
YoY Change -100.0%
INVESTING ACTIVITIES
Capital Expenditures $10.00K
YoY Change -100.78%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K
YoY Change -99.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -716.0K -50.00K
YoY Change 1332.0% -100.99%
NET CHANGE
Cash From Operating Activities 715.0K 0.000
Cash From Investing Activities -10.00K
Cash From Financing Activities -716.0K -50.00K
Net Change In Cash -1.000K -60.00K
YoY Change -98.33% -102.16%
FREE CASH FLOW
Cash From Operating Activities $715.0K $0.00
Capital Expenditures $10.00K
Free Cash Flow -$10.00K
YoY Change -103.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Goodwill
Goodwill
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
usd
CY2024Q3 us-gaap Other Income
OtherIncome
usd
CY2023Q3 us-gaap Other Income
OtherIncome
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40903
dei Entity Registrant Name
EntityRegistrantName
HEALTHCARE TRIANGLE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3559776
dei Entity Address Address Line1
EntityAddressAddressLine1
7901 Stoneridge Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 220
dei Entity Address City Or Town
EntityAddressCityOrTown
Pleasanton
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94588
dei City Area Code
CityAreaCode
(925)
dei Local Phone Number
LocalPhoneNumber
270-4812
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value
dei Trading Symbol
TradingSymbol
HCTI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5666781 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1234000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1610000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3236000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
146000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
824000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1784000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5294000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2965000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3972000 usd
CY2024Q3 us-gaap Assets
Assets
4766000 usd
CY2023Q4 us-gaap Assets
Assets
9614000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2298000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1953000 usd
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1333000 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
954000 usd
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
1082000 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
3429000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1371000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1787000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6084000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8123000 usd
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
500000 usd
CY2023Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
500000 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
453000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
6584000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
9076000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5666781 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5666781 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4308822 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4308822 shares
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27708000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25443000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29526000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24905000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1818000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
538000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4766000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9614000 usd
CY2024Q3 us-gaap Revenues
Revenues
2413000 usd
CY2023Q3 us-gaap Revenues
Revenues
7779000 usd
us-gaap Revenues
Revenues
9506000 usd
us-gaap Revenues
Revenues
26143000 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
1691000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
6072000 usd
us-gaap Cost Of Revenue
CostOfRevenue
6872000 usd
us-gaap Cost Of Revenue
CostOfRevenue
20896000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
175000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
509000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
695000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
294000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1101000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1808000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3888000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1077000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1364000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3157000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4604000 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
343000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
712000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1413000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2388000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1889000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3231000 usd
us-gaap Operating Expenses
OperatingExpenses
6887000 usd
us-gaap Operating Expenses
OperatingExpenses
11575000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1167000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1524000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4253000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6328000 usd
us-gaap Other Income
OtherIncome
12000 usd
CY2024Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-80000 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-415000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-360000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-663000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1247000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1939000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4613000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6979000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1249000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1943000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4621000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7007000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.9
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.65
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5666238 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5666238 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4277863 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4277863 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5147851 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5147851 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4245985 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4245985 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-646000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1249000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
77000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1818000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
538000 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
106000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
956000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1181000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4621000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1818000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8051000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1943000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
20000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6128000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12388000 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
197000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
499000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
51000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7007000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6128000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4621000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7007000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
379000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1034000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2388000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
22000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
51000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
106000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
197000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
217000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
75000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1626000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1396000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-678000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-194000 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-304000 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-1060000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
345000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-321000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-360000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-783000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-270000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2750000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000 usd
hcti Payment For Increase In Additional Paidup Capital
PaymentForIncreaseInAdditionalPaidupCapital
-956000 usd
hcti Payment For Increase In Additional Paidup Capital
PaymentForIncreaseInAdditionalPaidupCapital
-499000 usd
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-1892000 usd
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
992000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-936000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1491000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1206000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1266000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1234000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1341000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
360000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
663000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
8000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
28000 usd
us-gaap Stock Issued1
StockIssued1
1181000 usd
hcti Reclassification Of Contingent Consideration To Derivative Liability
ReclassificationOfContingentConsiderationToDerivativeLiability
740000 usd
CY2023Q4 us-gaap Stockholders Equity Period Increase Decrease
StockholdersEquityPeriodIncreaseDecrease
1181250000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements is in conformity with GAAP, which requires us to make estimates, judgments and assumptions that affect the financial statements and the notes thereto. These estimates are based on information available as of the date of the financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td>the standalone selling price for each distinct performance obligation</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td>the determination of the period of benefit for amortization of deferred costs.</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td>the fair value of assets acquired, and liabilities assumed for business combinations.</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td>Share based compensation including warrants</td></tr></table>
us-gaap Gross Profit
GrossProfit
1070000000.00 usd
CY2024Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1000000000 usd
CY2024Q3 us-gaap Revenues
Revenues
2413000 usd
CY2023Q3 us-gaap Revenues
Revenues
7779000 usd
CY2024Q3 hcti Changes In Revenue
ChangesInRevenue
-5366000 usd
CY2024Q3 hcti Percentage Of Changes In Revenue
PercentageOfChangesInRevenue
-0.69 pure
us-gaap Revenues
Revenues
9506000 usd
us-gaap Revenues
Revenues
26143000 usd
hcti Changes In Revenue
ChangesInRevenue
-16637000 usd
hcti Percentage Of Changes In Revenue
PercentageOfChangesInRevenue
-0.64 pure
CY2024Q3 hcti Segment Operatingloss Profit
SegmentOperatinglossProfit
114000 usd
CY2023Q3 hcti Segment Operatingloss Profit
SegmentOperatinglossProfit
108000 usd
CY2024Q3 hcti Changes In Segment Operatingloss Profit
ChangesInSegmentOperatinglossProfit
6000 usd
CY2024Q3 hcti Percentage Of Changes In Segment Operating Loss Profit
PercentageOfChangesInSegmentOperatingLossProfit
0.06 pure
CY2024Q3 hcti Unallocated Costsvalue
UnallocatedCostsvalue
1281000 usd
CY2023Q3 hcti Unallocated Costsvalue
UnallocatedCostsvalue
1632000 usd
CY2024Q3 hcti Changes In Unallocated Costs
ChangesInUnallocatedCosts
-351000 usd
CY2024Q3 hcti Percentage Of Unallocated Costs
PercentageOfUnallocatedCosts
-0.22 pure
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1167000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1524000 usd
CY2024Q3 hcti Changes In Incomeloss From Operations
ChangesInIncomelossFromOperations
357000 usd
CY2024Q3 hcti Percentage Of Incomeloss From Operations
PercentageOfIncomelossFromOperations
0.23 pure
CY2024Q3 hcti Other Income Percentage Changes
OtherIncomePercentageChanges
0 pure
CY2024Q3 us-gaap Interest Expense
InterestExpense
-80000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
-415000 usd
CY2024Q3 hcti Changes In Interest Expense
ChangesInInterestExpense
335000 usd
CY2024Q3 hcti Percentage Of Interest Expense
PercentageOfInterestExpense
0.81 pure
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1247000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1939000 usd
CY2024Q3 hcti Changes In Net Incomeloss Before Income Tax Expenses
ChangesInNetIncomelossBeforeIncomeTaxExpenses
692000 usd
CY2024Q3 hcti Percentage Of Net Incomeloss Before Income Tax Expenses
PercentageOfNetIncomelossBeforeIncomeTaxExpenses
0.36 pure
hcti Segment Operatingloss Profit
SegmentOperatinglossProfit
580000 usd
hcti Segment Operatingloss Profit
SegmentOperatinglossProfit
-676000 usd
hcti Changes In Segment Operatingloss Profit
ChangesInSegmentOperatinglossProfit
1256000 usd
hcti Percentage Of Changes In Segment Operating Loss Profit
PercentageOfChangesInSegmentOperatingLossProfit
1.86 pure
hcti Unallocated Costsvalue
UnallocatedCostsvalue
4833000 usd
hcti Unallocated Costsvalue
UnallocatedCostsvalue
5652000 usd
hcti Changes In Unallocated Costs
ChangesInUnallocatedCosts
-819000 usd
hcti Percentage Of Unallocated Costs
PercentageOfUnallocatedCosts
-0.14 pure
us-gaap Operating Income Loss
OperatingIncomeLoss
-4253000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6328000 usd
hcti Changes In Incomeloss From Operations
ChangesInIncomelossFromOperations
2075000 usd
hcti Percentage Of Incomeloss From Operations
PercentageOfIncomelossFromOperations
0.33 pure
us-gaap Other Noncash Income
OtherNoncashIncome
0 usd
us-gaap Other Noncash Income
OtherNoncashIncome
12000 usd
hcti Changes Amount Other Income
ChangesAmountOtherIncome
-12000 usd
hcti Other Income Percentage Changes
OtherIncomePercentageChanges
-1 pure
us-gaap Interest Expense
InterestExpense
-360000 usd
us-gaap Interest Expense
InterestExpense
-663000 usd
hcti Changes In Interest Expense
ChangesInInterestExpense
303000 usd
hcti Percentage Of Interest Expense
PercentageOfInterestExpense
0.46 pure
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4613000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6979000 usd
hcti Changes In Net Incomeloss Before Income Tax Expenses
ChangesInNetIncomelossBeforeIncomeTaxExpenses
2366000 usd
hcti Percentage Of Net Incomeloss Before Income Tax Expenses
PercentageOfNetIncomelossBeforeIncomeTaxExpenses
0.34 pure
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1610000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3236000 usd
CY2024Q3 hcti Allowances For Uncollectible Accounts
AllowancesForUncollectibleAccounts
63000 usd
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
222000 usd
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1333000 usd
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
500000 usd
CY2024Q3 hcti Consulting Expense
ConsultingExpense
22000 usd
us-gaap Advertising Expense
AdvertisingExpense
78000 usd
us-gaap Advertising Expense
AdvertisingExpense
155000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Concentrations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and trade receivables. Credit risks associated with trade receivables is minimal due to the Company’s customer base which consist of large customer base and ongoing procedures, which monitor the credit worthiness of its customers. For the quarter ended September 30, 2024 and 2023 revenue from the top five customers accounted for approximately 61% and 78% of total revenue respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains cash balances in various financial institutions. The balances are generally insured by the Federal Deposit Insurance Corporation up to $250,000 (valid through September 30, 2024) per institution.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024 and December 31, 2023, the Company had $0 and $667 respectively, of uninsured cash balances. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash.</p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000000 usd
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
667000 usd
CY2024Q3 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
132000 usd
CY2023Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
132000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
115000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
88000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000 usd
us-gaap Depreciation
Depreciation
7000 usd
us-gaap Depreciation
Depreciation
13000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
15887000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12922000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2965000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
15887000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11915000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3972000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
336000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
701000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
336000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1343000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1286000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2965000 usd
hcti Operating Leases Rent Expenses Net
OperatingLeasesRentExpensesNet
34000 usd
hcti Operating Leases Rent Expenses Net
OperatingLeasesRentExpensesNet
67000 usd
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
875000 usd
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1112000 usd
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
888000 usd
CY2024Q3 us-gaap Convertible Debt
ConvertibleDebt
875000 usd
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
2000000 usd
CY2024Q3 us-gaap Debt Instrument Convertible Liquidation Preference Per Share
DebtInstrumentConvertibleLiquidationPreferencePerShare
7.99
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 usd
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1333000 usd
CY2024Q3 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.01 pure
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
1082000 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
3429000 usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
658000 usd
CY2024Q3 hcti Adjusting Discount Rate
AdjustingDiscountRate
217000 usd
us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.50 pure
CY2024Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4380000 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3322000 usd
CY2024Q3 hcti Deferred Tax Assets Tax Stockbased Compensation Stockbased Compensation
DeferredTaxAssetsTaxStockbasedCompensationStockbasedCompensation
35000 usd
CY2023Q4 hcti Deferred Tax Assets Tax Stockbased Compensation Stockbased Compensation
DeferredTaxAssetsTaxStockbasedCompensationStockbasedCompensation
18000 usd
CY2024Q3 hcti Deferred Tax Assets Tax Warrants
DeferredTaxAssetsTaxWarrants
102000 usd
CY2023Q4 hcti Deferred Tax Assets Tax Warrants
DeferredTaxAssetsTaxWarrants
172000 usd
CY2024Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4243000 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3132000 usd
CY2024Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4243000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3132000 usd
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
8000 usd
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
28000 usd
us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
8000 usd
us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
28000 usd
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
8000 usd
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
28000 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
538265 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
17110 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
535375 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7531 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
527844 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
38584 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
566428 shares
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
135377 shares
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
21807 shares
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.58
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
17616 shares
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
4.22
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
95954 shares
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
12799 shares
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.84
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
83155 shares
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
15939 shares
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.85
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
67126 shares
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
70000 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
195000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1249000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1943000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5666238 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4277863 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
hcti Original Issue Discount Of Unsecured Convertible Promissory Note Percentage
OriginalIssueDiscountOfUnsecuredConvertiblePromissoryNotePercentage
0.20 pure
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 us-gaap Goodwill
Goodwill
usd
CY2024Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
usd
us-gaap Other Income
OtherIncome
usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Stock Issued1
StockIssued1
usd
hcti Reclassification Of Contingent Consideration To Derivative Liability
ReclassificationOfContingentConsiderationToDerivativeLiability
usd
CY2024Q3 us-gaap Other Noncash Income
OtherNoncashIncome
usd
CY2023Q3 us-gaap Other Noncash Income
OtherNoncashIncome
usd
CY2024Q3 hcti Changes Amount Other Income
ChangesAmountOtherIncome
usd
CY2023Q3 hcti Consulting Expense
ConsultingExpense
usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
usd
CY2024Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
usd
CY2024Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2024Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
usd
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
usd
CY2024Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
usd
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
shares
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001839285

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001213900-24-098548-index-headers.html Edgar Link pending
0001213900-24-098548-index.html Edgar Link pending
0001213900-24-098548.txt Edgar Link pending
0001213900-24-098548-xbrl.zip Edgar Link pending
ea0219026-10q_health.htm Edgar Link pending
ea021902601ex31-1_healthcare.htm Edgar Link pending
ea021902601ex31-2_healthcare.htm Edgar Link pending
ea021902601ex32-1_healthcare.htm Edgar Link pending
ea021902601ex32-2_healthcare.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hcti-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
hcti-20240930_cal.xml Edgar Link unprocessable
hcti-20240930_def.xml Edgar Link unprocessable
hcti-20240930_lab.xml Edgar Link unprocessable
hcti-20240930_pre.xml Edgar Link unprocessable
ea0219026-10q_health_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending